proLékaře.cz | 1.11.2026

Forum diabetologicum 2013; 2

Regisler kľúčových slov

kľúčové slovo	(číslo): strany
akútne srdcové zlyhávanie	(1): 23–26
akútny koronárny syndróm	(1): 23–26
aliskirén	(1): 11–17
antiagregační léčba	(2): 68–73
antidiabetiká	(1): 18–22
antihypertenzívne lieky	(1): 11–17
anti-VEGF	(3): 185–188
AT1-blokátory	(2): 68–73
aterogénna dyslipidémia	(2): 140–145
ateroskleróza	(2): 140–145
autonómna neuropatia	(2): 108–116
bazálne analógy inzulínu	(2): 130–139
cievy	(2): 90–97
cílová hodnota krevního tlaku	(2): 68–73
časná inzulinová terapie diabetu 2. typu	(3): 165–168
časná kombinační léčba	(3): 165–168
časná léčba diabetu	(3): 165–168
dermoepidermálne štepy	(2): 98–101
diabetes mellitus	(1): 18–22
	(1): 23–26
	(1): 27–30
	(1): 31–35
	(1): 36–40
	(2): 102–107
	(2): 108–116
	(2): 117–121
	(3): 190–192
diabetes mellitus 1. typu	(3): 185–188
diabetes mellitus 2. typu	(2): 122–124
diabetes mellitus-výskyt	(3): 193–199
diabetická kardiomyopatia	(1): 18–22
diabetická nefropatia	(1): 31–35
	(2): 117–121
	(S1): 1–6
diabetická noha	(2): 74–83
	(2): 90–97
	(2): 98–101
diabetická retinopatia	(3): 170–175
	(3): 176–180
	(3): 181–184
	(3): 193–199
diabetické ulcerace	(2): 102–107
diabetický edém makuly	(3): 170–175
	(3): 185–188
	(3): 193–199
diagnostika diabetickej nefropatie	(2): 117–121
dysliporoteinémia	(2): 140–145
endovaskulárne výkony	(2): 90–97
etiopatogenéza	(2): 84–89
glaukóm	(3): 190–192

kľúčové slovo	(číslo): strany
gliptíny	(2): 130–139
gravidita	(3): 176–180
	(3): 181–184
hypertriacylglycerolémie	(2): 140–145
hypolipidemika	(2): 68–73
chronická rana	(2): 98–101
indikačné obmedzenia	(2): 130–139
inhibitory ACE	(2): 68–73
intenzifikovaný inzulínový režim	(2): 122–124
inzulín lispro mix	(2): 122–124
jednoduchosť a finančná nenáročnosť	(2): 98–101
kardiorenálny syndróm	(1): 31–35
kardiovaskulárne ochorenia	(1): 27–30
kardiovaskulární mortalita	(2): 102–107
kardiovaskulární riziko	(3): 165–168
komorová fibrilácia	(1): 36–40
kompliancia	(1): 11–17
komplikácie	(2): 108–116
larvoterapia	(2): 74–83
laserová liečba	(3): 176–180
léčba prediabetu	(3): 165–168
liečba pomocou živých bunkových línií	(2): 74–83
liečba riadeným podtlakom	(2): 74–83
mikroalbuminúria	(2): 117–121
mikroalbuminurie	(2): 68–73
multiorgánovomultivaskulárna choroba	(1): 36–40
nefroprotekce	(2): 68–73
neovaskularizácie terča zrakového nervu	(3): 185–188
neovaskulárny glaukóm	(3): 190–192
pars plana vitrektómia	(3): 170–175
periférna neuropatia	(2): 108–116
podiatrické centrum	(2): 102–107
prediabetes	(3): 165–168
predsieňová fibrilácia	(1): 27–30
premixované inzulínové analógy	(2): 122–124
prevence diabetu	(3): 165–168
primárny glaukóm s otvoreným uhlom	(3): 190–192
ranibizumab	(3): 185–188
rehospitalizácie pre akútne ochorenia	(1): 23–26
rizikové faktory	(2): 84–89
skríning	(3): 176–180
srdcové zlyhávanie	(1): 18–22
syndróm diabetickej nohy	(2): 84–89
tehotenstvo	(3): 181–184
tlak vnutroočný	(3): 190–192
tolerancia	(1): 11–17
transplantácia autológnych štepov	(2): 98–101
trvanie účinku	(1): 11–17
zobrazovacie metódy	(2): 90–97

proLékaře.cz | 1.11.2026

Forum diabetologicum 2013; 2

Index of key words

key word	(číslo): strany
ACE inhibitors	(2): 68–73
acute coronary syndrome	(1): 23–26
acute heart failure	(1): 23–26
aliskiren	(1): 11–17
angiotensin receptor blockers	(2): 68–73
antidiabetics	(1): 18–22
antihypertensive drugs	(1): 11–17
antiplatelet therapy	(2): 68–73
anti-VEGF	(3): 185–188
atherogenic dyslipidemia	(2): 140–145
atherosclerosis	(2): 140–145
atrial fibrilation	(1): 27–30
autonomic neuropathy	(2): 108–116
basal insulin analogues	(2): 130–139
blood vessels	(2): 90–97
cardiorenal syndrome	(1): 31–35
cardiovascular disease	(1): 27–30
cardiovascular mortality	(2): 102–107
cardiovascular risk	(3): 165–168
compliance	(1): 11–17
complications	(2): 108–116
dermoepidermal skin grafts	(2): 98–101
diabetes mellitus	(1): 18–22
	(1): 23–26
	(1): 27–30
	(1): 31–35
	(1): 36–40
	(2): 102–107
	(2): 108–116
	(2): 117–121
	(3): 190–192
diabetes mellitus type 1	(3): 185–188
diabetes mellitus type 2	(2): 122–124
diabetes mellitus-incidence	(3): 193–199
diabetes prevention	(3): 165–168
diabetic cardiomyopathy	(1): 18–22
diabetic foot	(2): 74–83
	(2): 90–97
	(2): 98–101
diabetic foot clinic	(2): 102–107
diabetic foot syndrome	(2): 84–89
diabetic foot ulcer	(2): 102–107
diabetic macular edema	(3): 170–175
	(3): 185–188
	(3): 193–199
diabetic nephropathy	(1): 31–35
	(2): 117–121
	(S1): 1–6
diabetic retinopathy	(3): 170–175
	(3): 176–180
	(3): 181–184
	(3): 193–199
diagnosis of diabetic nephropathy	(2): 117–121
duration of action	(1): 11–17
dyslipoproteinemia	(2): 140–145
early combination treatment	(3): 165–168
early insulin treatment in type 2 diabetes	(3): 165–168
early treatment of diabetes	(3): 165–168
endovascular intervention	(2): 90–97
etiopathogenesis	(2): 84–89
forgiveness	(1): 11–17
glaucoma	(3): 190–192
gliptines	(2): 130–139
goal blood pressure	(2): 68–73
heart failure	(1): 18–22
hypertriglyceridemia	(2): 140–145
chronical wound	(2): 98–101
imaging methods	(2): 90–97
indicating restrictions	(2): 130–139
insulin lispro mix	(2): 122–124
intensified insulin regimen	(2): 122–124
intraocular pressure	(3): 190–192
laser treatment	(3): 176–180
lipid-lowering drugs	(2): 68–73
maggot therapy	(2): 74–83
microalbuminuria	(2): 68–73
	(2): 117–121
multiorganomultivascular arterial disease	(1): 36–40
neovascular glaucoma	(3): 190–192
nephroprotection	(2): 68–73
optic disc neovascularization	(3): 185–188
pars plana vitrektómia	(3): 170–175
peripheral neuropathy	(2): 108–116
prediabetes	(3): 165–168
prediabetes treatment	(3): 165–168
pregnancy	(3): 176–180
	(3): 181–184
premixed insulin analogues	(2): 122–124
primary open-angle glaucoma POAG	(3): 190–192
ranibizumab	(3): 185–188
rehospitalization for acute diseases	(1): 23–26
risk factors	(2): 84–89
screening	(3): 176–180
simplicity and low cost	(2): 98–101
transplatation of autolog skin grafts	(2): 98–101
treatment with controlled vacuum	(2): 74–83
treatment with live cell lines	(2): 74–83
ventricular fibrilation	(1): 36–40